The Maryland Prescription Drug Affordability Board (PDAB) found that Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga (dapagliflozin) present affordability ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

GSK's Q2 results show that sales of its specialist oncology assets have risen by 42%, while general drug sales were down 6%.

Analysts say the departure of the CBER head may alleviate overhang in the cell and gene therapy space. Vinay Prasad, head of the Center for Biologics Evaluation and Research (CBER) at the US Food and ...

MetrioPharm’s lead compound, MP1032, has received ODD from the European Medicines Agency (EMA) for treating DMD in children.

South Korea’s biopharmaceutical sector has seen a surge in innovator drug licensing agreements, reaching a total deal value of $7.86bn in 2025 year-to-date (YTD), at a 113% increase from 2024, ...

Despite being significantly lower than the 200% rate threatened by Trump, the deal is set to ramp up drug costs by billions.

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Re-Vana Therapeutics has entered a partnership and licence agreement with Boehringer Ingelheim for the development of eye therapies.

MSD has joined fellow big pharmas in looking to redirect cash, as the drugmaker revealed plans to save $3bn annually by the end of 2027.

A new report examines why linked data is essential to advancing healthcare and improving outcomes for patients.

The US biopharma has planted roots in the UK’s biotech cluster as it bets on synthetic rescue to unlock new treatments for rare diseases.